

Dechert
LLP**RECEIVED**
CENTRAL FAX CENTER**MAR 22 2006**1117 California Avenue
Palo Alto, CA 94304-1106
+1 650 813 4800 Main
+1 650 813 4848 Fax
www.dechert.com**FAX TRANSMISSION SHEET*****COURTESY COPY*****DATE** March 22, 2006

TO United States Patent and Trademark Office **TEL**
FAX 571 273 8300

FROM Ann M. Caviani Pease **TEL** +1 650 813 4851
Partner **FAX** +1 650 331 1962
EMAIL ann.pease@dechert.com

CLIENT 375462
MATTER 012US (355218)

TOTAL NUMBER OF PAGES, INCLUDING 3
THIS COVER SHEET

IF ALL PAGES ARE NOT RECEIVED,
PLEASE CALL +1 215 994 4000**OPERATOR****TIME OF TRANSMISSION**

CONFIDENTIALITY NOTE

The information contained in this facsimile message is legally privileged and confidential information intended only for the use of the individual or entity named above. If you are not the intended recipient, you are hereby notified that you should not further disseminate, distribute or copy this message. In addition, if you have received this message in error, please notify us immediately by collect telephone call and return the original message to us at the above address via the United States Postal Service. Thank you.

MESSAGE

Attached please find a Combined Revocation and Power of Attorney and Statement Under 37 CFR § 3.73(b) for the above-referenced matter.

12459463.1.BUSINESS

**COMBINED REVOCATION AND POWER OF ATTORNEY AND
STATEMENT UNDER 37 CFR §3.73(b)**

Rigel Pharmaceuticals, Inc. states that it is the assignee of the entire right, title, and interest to the patent applications/patents identified below by virtue of an assignment from the inventor(s) recorded at the specified reel and frame numbers:

| Dechert Attorney Docket No. | Serial No. | Title | Filed Date | Reel/Frame |
|--|-------------------|---|-------------------|-------------------|
| 375462-012US | 10/631,029 | Methods For Treating Or Preventing Diseases With 2, 4 Pyrimidinediamine Compounds | July 29, 2003 | 015937/0587 |

Assignee hereby revokes all previous powers of attorney and hereby appoints, both jointly and severally, Ann M. Caviani Pease, Registration No. 42,067, and the DECHERT LLP attorneys and agents associated with **Customer Number 37509** with full power of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office ("Office") connected herewith, said appointment to be to the exclusion of the inventor(s) and his/her attorney(s) in accordance with the provisions of 37 CFR § 3.71; provided that if any one of said attorneys or agents ceases being affiliated with the law firm of DECHERT LLP as partner, employee or of counsel, such attorneys' or agents' appointment and all powers derived there from shall terminate on the date such attorney or agent ceases being so affiliated.

Please address all telephone calls and correspondence to **Ann M. Caviani Pease** at the address corresponding to **Customer No. 37509**, currently:

DECHERT LLP
P.O. Box 10004
Palo Alto, CA 94304-1196
Tel: (650) 813-4800
Fax: (650) 813-4848

The undersigned (whose title is supplied below) is empowered to sign this statement on behalf of the assignee.

Assignee: **Rigel Pharmaceuticals, Inc.**

Name: Donald G. Payan

Title: EVP & CSO & Director

Date: 3.22.06

Signed:

Donald G. Payan

Address: **1180 Veterans Blvd.
South San Francisco, CA 94080**

12494312.1.BUSINESS